481 related articles for article (PubMed ID: 28792132)
1. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
4. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
6. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
8. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB
Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823
[TBL] [Abstract][Full Text] [Related]
9. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Fernando J; Malfettone A; Cepeda EB; Vilarrasa-Blasi R; Bertran E; Raimondi G; Fabra À; Alvarez-Barrientos A; Fernández-Salguero P; Fernández-Rodríguez CM; Giannelli G; Sancho P; Fabregat I
Int J Cancer; 2015 Feb; 136(4):E161-72. PubMed ID: 25053293
[TBL] [Abstract][Full Text] [Related]
10. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
12. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
13. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
15. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
17. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
[TBL] [Abstract][Full Text] [Related]
19. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
20. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]